The Consortium
The mission of the Pre-medical Cancer Immunotherapy Network for Canine Trials (PRECINCT) is to provide infrastructure and oversight to a highly collaborative and interactive network of researchers and clinician scientists working to accelerate the application of next generation immunotherapies through comparative oncology.
​
Coordinating Center:
​
Collaborative Network:
​
The Coordinating Center at the University of Pennsylvania provides comprehensive project oversight, supervises all project management and regulatory compliance activities, and coordinates site management for all aspects of single and large multi-site projects in PRECINCT.
​
Principal Investigators:
Dr. Nicola J. Mason, Department of Clinical Sciences & Advanced Medicine at the University of Pennsylvania.
Dr. Qi Long, Department of Biostatistics, Epidemiology, & Informatics, Perelman School of Medicine at the University of Pennsylvania
PennVet Research
https://www.vet.upenn.edu/research/centers-initiatives/mason-immunotherapy-research
​
Contact for Clinical Trials Information:
Natalie Kuzla, MA
University of Pennsylvania Coordinating Center
The Flint Animal Cancer Center at Colorado State University together with the Cummings Veterinary Medicine Center at Tufts University are conducting studies to assess the efficacy of combination immunotherapy approaches to treatment and prevention of tumor metastasis in dogs with osteosarcoma. These studies are being done in dogs with measurable osteosarcoma metastases, which will allow ready detection of treatment efficacy in a rapid time frame.
​
Project Synopses:
For Pet Owners:
Clinical Trials for Osteosarcoma Trial 1
​
Principal Investigators:
Dr. Steven Dow, veterinarian trained in immunology, microbiology, and cancer research, Flint Animal Cancer Center at Colorado State University
Dr. Cheryl London, veterinary medical oncologist trained in immunology,
Cummings Veterinary Medicine Center at Tufts University
Flint Animal Cancer Center at Colorado State University
300 W Drake Rd.
Fort Collins, CO 80525
https://www.csuanimalcancercenter.org/
​
Cummings Veterinary Medical Center
at Tufts University
200 Westboro Rd.
N. Grafton, MA 01536
​
Contact for Clinical Trials Information:
Colorado State University & Tufts University
The Cummings Veterinary Medical Center at Tufts University is conducting studies in dogs with Diffuse Large B-cell Lymphoma (DLBCL) to develop novel immunotherapy strategies that are effective or better than current therapies. The work his to evaluate novel combinations of immunotherapies in dogs with previously untreated DLBCL to identify the most promising approach, and then evaluate this against standard CHOP chemotherapy in a prospective clinical trial. Ultimately, the goal is to develop an effective chemotherapy free regime for DLBCL that can be rapidly translated into subsequent human trials.
​
Project Synopses:
Enhancing the efficacy of immunotherapy in DLBCL using rational combination approaches.
​
For Pet Owners:
Clinical Trials in B-Cell Lymphoma
​
Principal Investigator:
Dr. Cheryl London, veterinary medical oncologist trained in immunology,
Cummings Veterinary Medicine Center at Tufts University
Cummings Veterinary Medical Center
at Tufts University
200 Westboro Rd.
N. Grafton, MA 01536
Contact for Clinical Trials Information:
Cheryl London
Cornell University & Tufts University
Dr. M. Renee Chambers, DVM, MD, a neurosurgeon and veterinarian at The University of Alabama at Birmingham (UAB) - is partnering with veterinarians to conduct the first immunotherapy study for brain tumors in dogs using an oncolytic herpes simplex virus known as M032. The virus, developed at UAB, is currently being used in a clinical trial to treat humans with the same tumors. Care for pet dogs is now available at regional sites, including the Colleges of Veterinary Medicine at Mississippi State, Georgia and Auburn. This trial opens up an exciting new research pathway while providing the potential of a therapy that could benefit both humans and canines with brain tumors.
​
Project Synopses:
Canine ImmunoNeurotherapeutics
​
For Pet Owners:
​
Principal Investigator:
Dr. M. Renee Chamber, DVM, MD, neurosurgeon and veterinarian
The University of Alabama at Birmingham
1720 2nd Avenue South
Birmingham, AL 35294-3410
https://www.uab.edu/medicine/caninetrial/
Study and contact information:
uab.edu/medicine/caninetrial
or call (205) 975-7519
University of Alabama at Birmingham
Investigators at the UCDavis Comprehensive Cancer Center have teamed up with the UCDavis School of Veterinary Medicine to launch a series of investigative immunotherapy trials aimed at enhancing a patient's own natural killer cells using inhaled recombinant IL-15 and super-agonist IL-15 in naturally occurring canine cancers. The purpose of this study is to determine the maximum tolerated dose and efficacy of an immunotherapy protocol against metastatic osteosarcoma or melanoma growing within the lungs.
​
Project Synopses:
For Pet Owners:
Clinical Trials for Malignant Melanoma
Clinical Trials for Osteosarcoma Trial 2
​
Principal Investigator:
Dr. Rob Rebhun; Maxine Adler Chair in Oncology
University of California Davis, School of Veterinary Medicine
​
Dr. Robert Canter; Professor of Surgery
University of California Davis, School of Medicine
University of California Davis,
School of Veterinary Medicine
944 Garrod Drive
Davis, CA 95616
​
Contact: oncologyclinicaltrials@ucdavis.edu
University of California - Davis
Dr. Rob Rebhun
Maxine Adler Chair in Oncology
University of California Davis,
School of Veterinary Medicine
Dr. Robert Canter
Professor of Surgery
University of California Davis,
School of Medicine
The Veterinary Medical Center at the University of Minnesota is conducting a study in dogs with high-grade glioma including glioblastoma (GBM), common primary malignant brain tumors, to develop novel immunotherapy strategies that are more effective than current treatments. These tumors are uniformly deadly in both dogs and people with median survival times of a few months in dogs and approximately 14 months in people after standard of care treatment. This work aims to evaluate novel combinations of immune therapies in dogs with previously untreated brain tumors to determine the combination that provides the longest remission times with minimal adverse effects. Our ultimately goal is to develop a safe and effective postoperative treatment that avoids the standard chemotherapy and radiation therapy that can be translated into human GBM patients.
​
Project Synopses:
For Pet Owners:
​
Principal Investigator:
Dr. Liz Pluhar (PI), veterinary surgeon trained in neurosurgery,
Veterinary Medicine Center at the University of Minnesota
​
Dr. Michael Olin (co-PI), veterinary immunologist
Developing vaccine-based immunotherapies,
Masonic Cancer Center at the University of Minnesota
Dr. Maria Castro (co-I), research scientist in neuroimmunology
Developing viral-mediated gene therapies,
Medical School at the University of Michigan.
​
The Veterinary Medical Center at
the University of Minnesota
1365 Gortner Ave,
St Paul, MN 55108
Contact for Clinical Trials Information:
Dr. Elizabeth Pluhar